ARK Genomic Revolution ETF ARKG
48.47 USD +3.02 (+6.64%)
Nov 9, 2026, 2:56 PM EST
45.47 Day range 48.74
24.60 52-week range 58.83
- YTD
- +67.31%
- 1 year
- +72.92%
News
benzinga.com Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
benzinga.com Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
benzinga.com Why Is Tempus AI Stock Falling Friday? Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally still intact? Read more.
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
benzinga.com What’s Going On With Tempus AI Stock on Monday? Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
benzinga.com Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
benzinga.com Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation? Cathie Wood sold $10M of Robinhood while adding $15M to SpaceX and boosting Archer Aviation. Here's what ARK Invest's ETF rotation signals.
benzinga.com Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD market.
benzinga.com Why Is Natera Stock Gaining Tuesday? Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
benzinga.com Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vaccine, lifting the leveraged MRNX ETF more than 60%.
benzinga.com Cathie Wood, Bill Ackman Share 3 Stock Investments In Common: Can You Guess What They Are? Cathie Wood and Bill Ackman are both betting on three of the same Magnificent Seven stocks.
benzinga.com Cathie Wood Slams The Brakes — Ark Invest Sits Out As S&P 500 Smashes Records Ark Invest made no trades in its six main ETFs for two straight days, a rare feat. Here's how the ETFs are performing in 2026.
benzinga.com Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
benzinga.com Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note? Cathie Wood and Ark Invest have been snatching up shares of a small cap diagnostics company for seven straight days. Here's the stock.
benzinga.com What's Going On With Tempus AI Stock Monday? Ambry Genetics, a subsidiary of Tempus AI, announced completion of 1 million DNA/RNA tests for hereditary cancer and rare disease.
benzinga.com FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted treatment.
benzinga.com Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes for 2026 that investors should watch.
benzinga.com Cathie Wood Beats S&P 500 in 2025 — This ARK ETF Delivered The Knockout With A 50% Gain Ark Invest saw its main ETFs beat the S&P 500 performance in 2025. Here's a look at the top performing ETF from the Cathie Wood company and its top holdings.
benzinga.com Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
benzinga.com Beyond S&P 500: KKR Flags Asia, Biotech, Infrastructure As Next 'High-Grade' Trades For 2026 KKR's 2026 Outlook finds value beyond the S&P 500. Explore investment strategies in Asia, biotech, and critical infrastructure.
benzinga.com Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025.
benzinga.com Wellgistics And DataVault Team Up To Transform Prescription Tracking DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.
benzinga.com Trump's Weight-Loss Drug Push May Put These ETFs On A Diet Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.
benzinga.com Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.
benzinga.com Cathie Wood's Ark Invest Loads Up On Coinbase, Roku, Illumina, And Bitmine Immersion Cathie Wood-led Ark Invest made significant trades in COIN, ROKU, ILMN, and BMNR. They also bought PD and SOFI, sold KTOS and RBLX.
benzinga.com Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
benzinga.com Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025.
benzinga.com Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.
benzinga.com Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx.
benzinga.com Rocket Lab, Kratos, Archer Aviation And More Earnings This Week Could Have A Big Impact On Cathie Wood's Ark ETFs Several top Cathie Wood holdings in the Ark Funds ETFs report quarterly results the week of Feb. 24 through Feb. 28.
benzinga.com NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
benzinga.com ETFs Shine As S&P 500 Hits Record High: Top 5 ETFs With Best Gains From Last Week Global economy and financial markets saw a lot of activity in Jan. 24 week. S&P 500 reached record high, several ETFs had double-digit gains.
benzinga.com Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units.
benzinga.com Is Cathie Wood The Next Warren Buffett? Apple, Tesla Define Their Investment Strategies With a track record of 60-plus years of strong returns for investors, Warren Buffett, who turns 93 Wednesday, is considered one of the all-time- benzinga.com Move Over, ChatGPT: 5 Stock Ideas For Leveraging The Power Of AI In Health Care, Cybersecurity Generative artificial intelligence has taken the world by storm in 2023.
benzinga.com Q2 Growth 'Nothing Short Of Virtuous': Economist The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic.
benzinga.com 4 ETFs To Watch In 2021 In the exchange traded funds industry, records are seemingly always being shattered and that's the case again in 2021. As of Dec. 17, $509.4 billion flowed into ETFs this year, topping the previous…